Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oruka Therapeutics, Inc. - Common Stock (NQ:ORKA)

32.91 -1.64 (-4.75%)
Streaming Delayed Price Updated: 2:51 PM EST, Feb 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Oruka Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics to Present at Multiple March Investor Conferences
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Discover the top movers in Tuesday's pre-market session. ↗
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
This Expand Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
PayPal, Estée Lauder, UBS And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Applied Digital, Vericel, Calavo Growers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Vision Marine Technologies Shares Are Trading Higher By 68%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics to Present at Piper Sandler’s 36th Annual Healthcare Conference
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics to Present at Multiple November Investor Conferences
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why DocuSign Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Announces $200 Million Private Placement
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001’s Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19
From Oruka Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.